{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:52:34Z","timestamp":1790175154645,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00401-019-02002-2","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T21:02:33Z","timestamp":1554757353000},"page":"625-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["An update on the central nervous system manifestations of neurofibromatosis type 1"],"prefix":"10.1007","volume":"139","author":[{"given":"J. Stephen","family":"Nix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-1219","authenticated-orcid":false,"given":"Fausto J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"2002_CR1","doi-asserted-by":"publisher","first-page":"6712","DOI":"10.1093\/hmg\/ddu389","volume":"23","author":"C Anastasaki","year":"2014","unstructured":"Anastasaki C, Gutmann DH (2014) Neuronal NF1\/RAS regulation of cyclic AMP requires atypical PKC activation. Hum Mol Genet 23:6712\u20136721. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddu389","journal-title":"Hum Mol Genet"},{"key":"2002_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/ppo.0000000000000020","volume":"20","author":"CL Appin","year":"2014","unstructured":"Appin CL, Brat DJ (2014) Molecular genetics of gliomas. Cancer J 20:66\u201372. \nhttps:\/\/doi.org\/10.1097\/ppo.0000000000000020","journal-title":"Cancer J"},{"key":"2002_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamaophthalmol.2013.7649","volume":"132","author":"RA Avery","year":"2014","unstructured":"Avery RA, Hwang EI, Ishikawa H, Acosta MT, Hutcheson KA, Santos D et al (2014) Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol 132:265\u2013271. \nhttps:\/\/doi.org\/10.1001\/jamaophthalmol.2013.7649","journal-title":"JAMA Ophthalmol"},{"key":"2002_CR4","doi-asserted-by":"publisher","first-page":"e49222","DOI":"10.1371\/journal.pone.0049222","volume":"7","author":"A Bajaj","year":"2012","unstructured":"Bajaj A, Li QF, Zheng Q, Pumiglia K (2012) Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis. PLoS One 7:e49222. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0049222","journal-title":"PLoS One"},{"key":"2002_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q","volume":"33","author":"ML Bajenaru","year":"2001","unstructured":"Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A et al (2001) Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33:314\u2013323. \nhttps:\/\/doi.org\/10.1002\/1098-1136(20010315)33:4%3c314:AID-GLIA1030%3e3.0.CO;2-Q","journal-title":"Glia"},{"key":"2002_CR6","first-page":"8573","volume":"63","author":"ML Bajenaru","year":"2003","unstructured":"Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR et al (2003) Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63:8573","journal-title":"Cancer Res"},{"key":"2002_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T et al (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19:1135\u20131144. \nhttps:\/\/doi.org\/10.1093\/neuonc\/now282","journal-title":"Neuro Oncol"},{"key":"2002_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eplepsyres.2013.02.021","volume":"105","author":"C Barba","year":"2013","unstructured":"Barba C, Jacques T, Kahane P, Polster T, Isnard J, Leijten FSS et al (2013) Epilepsy surgery in neurofibromatosis type 1. Epilepsy Res 105:384\u2013395. \nhttps:\/\/doi.org\/10.1016\/j.eplepsyres.2013.02.021","journal-title":"Epilepsy Res"},{"key":"2002_CR9","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1523\/JNEUROSCI.23-18-07207.2003","volume":"23","author":"MR Bennett","year":"2003","unstructured":"Bennett MR, Rizvi TA, Karyala S, McKinnon RD, Ratner N (2003) Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. J Neurosci 23:7207","journal-title":"J Neurosci"},{"key":"2002_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/hmg\/ddv635","volume":"25","author":"WK Bessler","year":"2016","unstructured":"Bessler WK, Kim G, Hudson FZ, Mund JA, Mali R, Menon K et al (2016) Nf1+\/- monocytes\/macrophages induce neointima formation via CCR2 activation. Hum Mol Genet 25:1129\u20131139. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddv635","journal-title":"Hum Mol Genet"},{"key":"2002_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/nov200","volume":"18","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Plotkin SR (2016) Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 18:624\u2013638. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nov200","journal-title":"Neuro Oncol"},{"key":"2002_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mcn.2011.08.008","volume":"49","author":"JA Brown","year":"2012","unstructured":"Brown JA, Diggs-Andrews KA, Gianino SM, Gutmann DH (2012) Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP\/PKA\/ROCK-dependent manner. Mol Cell Neurosci 49:13\u201322. \nhttps:\/\/doi.org\/10.1016\/j.mcn.2011.08.008","journal-title":"Mol Cell Neurosci"},{"key":"2002_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mcn.2011.08.008","volume":"49","author":"JA Brown","year":"2012","unstructured":"Brown JA, Diggs-Andrews KA, Gianino SM, Gutmann DH (2012) Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP\/PKA\/ROCK-dependent manner. Mol Cell Neurosci 49:13\u201322. \nhttps:\/\/doi.org\/10.1016\/j.mcn.2011.08.008","journal-title":"Mol Cell Neurosci"},{"key":"2002_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2011.09.005","volume":"232","author":"JA Brown","year":"2011","unstructured":"Brown JA, Xu J, Diggs-Andrews KA, Wozniak DF, Mach RH, Gutmann DH (2011) PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp Neurol 232:333\u2013338. \nhttps:\/\/doi.org\/10.1016\/j.expneurol.2011.09.005","journal-title":"Exp Neurol"},{"key":"2002_CR15","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.1523\/JNEUROSCI.0283-10.2010","volume":"30","author":"ME Buchanan","year":"2010","unstructured":"Buchanan ME, Davis RL (2010) A distinct set of drosophila brain neurons required for NF1-dependent learning and memory. J Neurosci 30:10135\u201310143. \nhttps:\/\/doi.org\/10.1523\/JNEUROSCI.0283-10.2010","journal-title":"J Neurosci"},{"key":"2002_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11060-017-2475-z","volume":"133","author":"S Byrne","year":"2017","unstructured":"Byrne S, Connor S, Lascelles K, Siddiqui A, Hargrave D, Ferner RE (2017) Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. J Neurooncol 133:609\u2013614. \nhttps:\/\/doi.org\/10.1007\/s11060-017-2475-z","journal-title":"J Neurooncol"},{"key":"2002_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/jnnp.2007.136457","volume":"79","author":"AG Cairns","year":"2008","unstructured":"Cairns AG, North KN (2008) Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 79:1165. \nhttps:\/\/doi.org\/10.1136\/jnnp.2007.136457","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2002_CR18","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1200\/JCO.2016.71.7199","volume":"35","author":"J Campian","year":"2017","unstructured":"Campian J, Gutmann DH (2017) CNS tumors in neurofibromatosis. J Clin Oncol 35:2378\u20132385. \nhttps:\/\/doi.org\/10.1200\/JCO.2016.71.7199","journal-title":"J Clin Oncol"},{"key":"2002_CR19","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","volume":"286","author":"K Cichowski","year":"1999","unstructured":"Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME et al (1999) Mouse models of tumor development in neurofibromatosis type 1. Science 286:2172","journal-title":"Science"},{"key":"2002_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","volume":"129","author":"VP Collins","year":"2015","unstructured":"Collins VP, Jones DTW, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:775\u2013788. \nhttps:\/\/doi.org\/10.1007\/s00401-015-1410-7","journal-title":"Acta Neuropathol"},{"key":"2002_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M et al (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415:526. \nhttps:\/\/doi.org\/10.1038\/nature711","journal-title":"Nature"},{"key":"2002_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V et al (2019) The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med 25:176\u2013187. \nhttps:\/\/doi.org\/10.1038\/s41591-018-0263-8","journal-title":"Nat Med"},{"key":"2002_CR23","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","volume":"65","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1\u2013associated human and mouse brain tumors. Cancer Res 65:2755","journal-title":"Cancer Res"},{"key":"2002_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","volume":"69","author":"JE DeClue","year":"1992","unstructured":"DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC et al (1992) Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265\u2013273. \nhttps:\/\/doi.org\/10.1016\/0092-8674(92)90407-4","journal-title":"Cell"},{"key":"2002_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ana.24093","volume":"75","author":"KA Diggs-Andrews","year":"2014","unstructured":"Diggs-Andrews KA, Brown JA, Gianino SM, Rubin JB, Wozniak DF, Gutmann DH (2014) Sex is a major determinant of neuronal dysfunction in Neurofibromatosis Type 1. Ann Neurol 75:309\u2013316. \nhttps:\/\/doi.org\/10.1002\/ana.24093","journal-title":"Ann Neurol"},{"key":"2002_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ana.23793","volume":"73","author":"KA Diggs-Andrews","year":"2013","unstructured":"Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH (2013) Dopamine deficiency underlies learning deficits in Neurofibromatosis-1 mice. Ann Neurol 73:309\u2013315. \nhttps:\/\/doi.org\/10.1002\/ana.23793","journal-title":"Ann Neurol"},{"key":"2002_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1148\/radiology.195.3.7754001","volume":"195","author":"DP DiPaolo","year":"1995","unstructured":"DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachnis AT (1995) Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 195:721\u2013724. \nhttps:\/\/doi.org\/10.1148\/radiology.195.3.7754001","journal-title":"Radiology"},{"key":"2002_CR28","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A et al (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375:2550\u20132560. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1605943","journal-title":"N Engl J Med"},{"key":"2002_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0304-419X(01)00041-5","volume":"1602","author":"S Donovan","year":"2002","unstructured":"Donovan S, Shannon KM, Bollag G (2002) GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 1602:23\u201345. \nhttps:\/\/doi.org\/10.1016\/S0304-419X(01)00041-5","journal-title":"Biochim Biophys Acta"},{"key":"2002_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11. \nhttps:\/\/doi.org\/10.1038\/nrc969","journal-title":"Nat Rev Cancer"},{"key":"2002_CR31","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","volume":"23","author":"DGR Evans","year":"2017","unstructured":"Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Schneider KW et al (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23:e46","journal-title":"Clin Cancer Res"},{"key":"2002_CR32","doi-asserted-by":"publisher","first-page":"10504","DOI":"10.1200\/JCO.2017.35.15_suppl.10504","volume":"35","author":"JR Fangusaro","year":"2017","unstructured":"Fangusaro JR, Onar-Thomas A, Young-Poussaint T, Wu S, Ligon AH, Lindeman NI et al (2017) A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): a Pediatric Brain Tumor Consortium (PBTC) study. J Clin Oncol 35:10504\u201310504. \nhttps:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.10504","journal-title":"J Clin Oncol"},{"key":"2002_CR33","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","volume":"81","author":"MJ Fisher","year":"2013","unstructured":"Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE et al (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 81:S15","journal-title":"Neurology"},{"key":"2002_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ana.21107","volume":"61","author":"ME Freret","year":"2007","unstructured":"Freret ME, Gutmann DH (2007) Understanding vision loss from optic pathway glioma in neurofibromatosis type 1. Ann Neurol 61:189\u2013198. \nhttps:\/\/doi.org\/10.1002\/ana.21107","journal-title":"Ann Neurol"},{"key":"2002_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00125817-200205000-00002","volume":"4","author":"JM Friedman","year":"2002","unstructured":"Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE et al (2002) Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 4:105. \nhttps:\/\/doi.org\/10.1097\/00125817-200205000-00002","journal-title":"Genet Med"},{"key":"2002_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jocn.2016.10.048","volume":"37","author":"J Gales","year":"2017","unstructured":"Gales J, Prayson RA (2017) Hippocampal sclerosis and associated focal cortical dysplasia-related epilepsy in neurofibromatosis type I. J Clin Neurosci 37:15\u201319. \nhttps:\/\/doi.org\/10.1016\/j.jocn.2016.10.048","journal-title":"J Clin Neurosci"},{"key":"2002_CR37","doi-asserted-by":"publisher","first-page":"e1642","DOI":"10.1542\/peds.2013-1868","volume":"132","author":"S Garg","year":"2013","unstructured":"Garg S, Green J, Leadbitter K, Emsley R, Lehtonen A, Evans DG et al (2013) Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics 132:e1642\u20131648. \nhttps:\/\/doi.org\/10.1542\/peds.2013-1868","journal-title":"Pediatrics"},{"key":"2002_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B","volume":"45","author":"J Grill","year":"2001","unstructured":"Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C et al (2001) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 45:393\u2013396. \nhttps:\/\/doi.org\/10.1002\/1531-8249(199903)45:3%3c393:AID-ANA17%3e3.0.CO;2-B","journal-title":"Ann Neurol"},{"key":"2002_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/brain\/awg016","volume":"126","author":"JS Guillamo","year":"2003","unstructured":"Guillamo JS, Cr\u00e9ange A, Kalifa C, Grill J, Rodriguez D, Barbarot S, for the R\u00e9seau NFF et al (2003) Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1)A retrospective study of 104 patients. Brain 126:152\u2013160. \nhttps:\/\/doi.org\/10.1093\/brain\/awg016","journal-title":"Brain"},{"key":"2002_CR40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/088307380201700809","volume":"17","author":"DH Gutmann","year":"2002","unstructured":"Gutmann DH (2002) Review article: neurofibromin in the brain. J Child Neurol 17:592\u2013601. \nhttps:\/\/doi.org\/10.1177\/088307380201700809","journal-title":"J Child Neurol"},{"key":"2002_CR41","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. \nhttps:\/\/doi.org\/10.1038\/nrdp.2017.4","journal-title":"Nat Rev Dis Primers"},{"key":"2002_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.neo.7900249","volume":"4","author":"DH Gutmann","year":"2002","unstructured":"Gutmann DH, Giovannini M (2002) Mouse Models of Neurofibromatosis 1 and 2. Neoplasia 4:279\u2013290. \nhttps:\/\/doi.org\/10.1038\/sj.neo.7900249","journal-title":"Neoplasia"},{"key":"2002_CR43","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1038\/sj.onc.1202829","volume":"18","author":"DH Gutmann","year":"1999","unstructured":"Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A (1999) Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18:4450. \nhttps:\/\/doi.org\/10.1038\/sj.onc.1202829","journal-title":"Oncogene"},{"key":"2002_CR44","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.59.5.759","volume":"59","author":"DH Gutmann","year":"2002","unstructured":"Gutmann DH, Rasmussen SA, Wolkenstein P, MacCollin MM, Guha A, Inskip PD et al (2002) Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59:759","journal-title":"Neurology"},{"key":"2002_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1034\/j.1399-0004.2000.580501.x","volume":"58","author":"SJ Hamilton","year":"2001","unstructured":"Hamilton SJ, Friedman JM (2001) Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet 58:341\u2013344. \nhttps:\/\/doi.org\/10.1034\/j.1399-0004.2000.580501.x","journal-title":"Clin Genet"},{"key":"2002_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.stem.2007.07.008","volume":"1","author":"B Hegedus","year":"2007","unstructured":"Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L et al (2007) Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in\u00a0vivo by both cAMP- and ras-dependent mechanisms. Cell Stem Cell 1:443\u2013457. \nhttps:\/\/doi.org\/10.1016\/j.stem.2007.07.008","journal-title":"Cell Stem Cell"},{"key":"2002_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","volume":"104","author":"J Helfferich","year":"2016","unstructured":"Helfferich J, Nijmeijer R, Brouwer OF, Boon M, Fock A, Hoving EW et al (2016) Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol 104:30\u201341. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2016.05.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2002_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","volume":"104","author":"J Helfferich","year":"2016","unstructured":"Helfferich J, Nijmeijer R, Brouwer OF, Boon M, Fock A, Hoving EW et al (2016) Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol 104:30\u201341. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2016.05.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2002_CR49","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1523\/JNEUROSCI.0933-07.2007","volume":"27","author":"IS Ho","year":"2007","unstructured":"Ho IS, Hannan F, Guo H-F, Hakker I, Zhong Y (2007) Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation. J Neurosci 27:6852","journal-title":"J Neurosci"},{"key":"2002_CR50","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.seizure.2011.04.016","volume":"20","author":"H-Y Hsieh","year":"2011","unstructured":"Hsieh H-Y, Fung H-C, Wang C-J, Chin S-C, Wu T (2011) Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure 20:606\u2013611. \nhttps:\/\/doi.org\/10.1016\/j.seizure.2011.04.016","journal-title":"Seizure"},{"key":"2002_CR51","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","volume":"65","author":"SL Hyman","year":"2005","unstructured":"Hyman SL, Shores A, North KN (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037","journal-title":"Neurology"},{"key":"2002_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/ng0794-353","volume":"7","author":"T Jacks","year":"1994","unstructured":"Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genet 7:353. \nhttps:\/\/doi.org\/10.1038\/ng0794-353","journal-title":"Nature Genet"},{"key":"2002_CR53","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME et al (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123:340\u2013347. \nhttps:\/\/doi.org\/10.1172\/JCI60578","journal-title":"J Clin Invest"},{"key":"2002_CR54","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s00018-011-0898-9","volume":"69","author":"DTW Jones","year":"2012","unstructured":"Jones DTW, Gronych J, Lichter P, Witt O, Pfister SM (2012) MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 69:1799\u20131811. \nhttps:\/\/doi.org\/10.1007\/s00018-011-0898-9","journal-title":"Cell Mol Life Sci"},{"key":"2002_CR55","doi-asserted-by":"publisher","first-page":"e47854","DOI":"10.1371\/journal.pone.0047854","volume":"7","author":"KH Karlsgodt","year":"2012","unstructured":"Karlsgodt KH, Rosser T, Lutkenhoff ES, Cannon TD, Silva A, Bearden CE (2012) Alterations in white matter microstructure in neurofibromatosis-1. PLoS One 7:e47854. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0047854","journal-title":"PLoS One"},{"key":"2002_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/cns-2016-0024","volume":"6","author":"S Karmakar","year":"2017","unstructured":"Karmakar S, Reilly KM (2017) The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol 6:45\u201360. \nhttps:\/\/doi.org\/10.2217\/cns-2016-0024","journal-title":"CNS Oncol"},{"key":"2002_CR57","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jocn.2011.12.013","volume":"19","author":"S Kemp","year":"2012","unstructured":"Kemp S, Achan A, Ng T, Dexter MAJ (2012) Rosette-forming glioneuronal tumour of the lateral ventricle in a patient with neurofibromatosis 1. J Clin Neurosci 19:1180\u20131181. \nhttps:\/\/doi.org\/10.1016\/j.jocn.2011.12.013","journal-title":"J Clin Neurosci"},{"key":"2002_CR58","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00125817-199905000-00004","volume":"1","author":"BR Korf","year":"1999","unstructured":"Korf BR, Schneider G, Poussaint TY (1999) Structural anomalies revealed by neuroimaging studies in the brains of patients with neurofibromatosis type 1 and large deletions. Genet Med 1:136\u2013140. \nhttps:\/\/doi.org\/10.1097\/00125817-199905000-00004","journal-title":"Genet Med"},{"key":"2002_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0887-8994(98)00075-7","volume":"19","author":"K Kulkantrakorn","year":"1998","unstructured":"Kulkantrakorn K, Geller TJ (1998) Seizures in neurofibromatosis 1. Pediatr Neurol 19:347\u2013350. \nhttps:\/\/doi.org\/10.1016\/S0887-8994(98)00075-7","journal-title":"Pediatr Neurol"},{"key":"2002_CR60","doi-asserted-by":"publisher","first-page":"e0178711","DOI":"10.1371\/journal.pone.0178711","volume":"12","author":"A Kurtelius","year":"2017","unstructured":"Kurtelius A, Kallionp\u00e4\u00e4 RA, Huttunen J, Huttunen TJ, Helin K, Koivisto T, Fr\u00f6sen J, von Und Zu et al (2017) Neurofibromatosis type 1 is not associated with subarachnoid haemorrhage. PLoS ONE 12:e0178711\u2013e0178711. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0178711","journal-title":"PLoS ONE"},{"key":"2002_CR61","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","volume":"59","author":"N Lau","year":"2000","unstructured":"Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH et al (2000) Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3-K\/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 59:759\u2013767. \nhttps:\/\/doi.org\/10.1093\/jnen\/59.9.759","journal-title":"J Neuropathol Exp Neurol"},{"key":"2002_CR62","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1093\/hmg\/ddq395","volume":"19","author":"J-S Lee","year":"2010","unstructured":"Lee J-S, Padmanabhan A, Shin J, Zhu S, Guo F, Kanki JP et al (2010) Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene. Hum Mol Genet 19:4643\u20134653. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddq395","journal-title":"Hum Mol Genet"},{"key":"2002_CR63","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-019-01960-x","volume":"137","author":"JC Lee","year":"2019","unstructured":"Lee JC, Villanueva-Meyer JE, Ferris SP, Sloan EA, Hofmann JW, Hattab EM et al (2019) Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol 137:521\u2013525. \nhttps:\/\/doi.org\/10.1007\/s00401-019-01960-x","journal-title":"Acta Neuropathol"},{"key":"2002_CR64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF00296517","volume":"90","author":"A Lellouch-Tubiana","year":"1995","unstructured":"Lellouch-Tubiana A, Bourgeois M, Vekemans M, Robain O (1995) Dysembryoplastic neuroepithelial tumors in two children with neurofibromatosis type 1. Acta Neuropathol 90:319\u2013322. \nhttps:\/\/doi.org\/10.1007\/BF00296517","journal-title":"Acta Neuropathol"},{"key":"2002_CR65","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/hmg\/ddl114","volume":"15","author":"F Li","year":"2006","unstructured":"Li F, Munchhof AM, White HA, Mead LE, Krier TR, Fenoglio A, Chen S, Wu X et al (2006) Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum Mol Genet 15:1921\u20131930. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddl114","journal-title":"Hum Mol Genet"},{"key":"2002_CR66","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13023-014-0142-4","volume":"9","author":"L Lion-Francois","year":"2014","unstructured":"Lion-Francois L, Gueyffier F, Mercier C, Gerard D, Herbillon V, Kemlin I et al (2014) The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. Orphanet J Rare Dis 9:142. \nhttps:\/\/doi.org\/10.1186\/s13023-014-0142-4","journal-title":"Orphanet J Rare Dis"},{"key":"2002_CR67","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/01.WNL.0000144341.16830.01","volume":"63","author":"R Listernick","year":"2004","unstructured":"Listernick R, Ferner RE, Piersall L, Sharif S, Gutmann DH, Charrow J (2004) Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 63:1944\u20131946","journal-title":"Neurology"},{"key":"2002_CR68","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/NEN.0000000000000113","volume":"73","author":"S Lummus","year":"2014","unstructured":"Lummus S, Breeze R, Lucia MS, Kleinschmidt-DeMasters BK (2014) Histopathologic features of intracranial vascular involvement in fibromuscular dysplasia, ehlers-danlos type IV, and neurofibromatosis I. J Neuropathol Exp Neurol 73:916\u2013932. \nhttps:\/\/doi.org\/10.1097\/NEN.0000000000000113","journal-title":"J Neuropathol Exp Neurol"},{"key":"2002_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/aur.1853","volume":"11","author":"SE Maloney","year":"2018","unstructured":"Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD (2018) Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. Autism Res 11:44\u201358. \nhttps:\/\/doi.org\/10.1002\/aur.1853","journal-title":"Autism Res"},{"key":"2002_CR70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3\u00a0K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320\u2013328. \nhttps:\/\/doi.org\/10.1016\/j.tibs.2011.03.006","journal-title":"Trends Biochem Sci"},{"key":"2002_CR71","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/GIM.0b013e3181cdd687","volume":"12","author":"DM Milewicz","year":"2010","unstructured":"Milewicz DM, Kwartler CS, Papke CL, Regalado ES, Cao J, Reid AJ (2010) Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy. Genet Med 12:196\u2013203. \nhttps:\/\/doi.org\/10.1097\/GIM.0b013e3181cdd687","journal-title":"Genet Med"},{"key":"2002_CR72","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1007\/s12035-016-9907-1","volume":"54","author":"A Moutal","year":"2017","unstructured":"Moutal A, Dustrude ET, Khanna R (2017) Sensitization of ion channels contributes to central and peripheral dysfunction in neurofibromatosis type 1. Mol Neurobiol 54:3342\u20133349. \nhttps:\/\/doi.org\/10.1007\/s12035-016-9907-1","journal-title":"Mol Neurobiol"},{"key":"2002_CR73","doi-asserted-by":"crossref","unstructured":"Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference (1988) Arch Neurol 45:575-578","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"2002_CR74","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jvs.2007.03.055","volume":"46","author":"GS Oderich","year":"2007","unstructured":"Oderich GS, Sullivan TM, Bower TC, Gloviczki P, Miller DV, Babovic-Vuksanovic D et al (2007) Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. J Vasc Surg 46:475\u2013484.e471. \nhttps:\/\/doi.org\/10.1016\/j.jvs.2007.03.055","journal-title":"J Vasc Surg"},{"key":"2002_CR75","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11060-010-0509-x","volume":"104","author":"JJ Otero","year":"2011","unstructured":"Otero JJ, Rowitch D, Vandenberg S (2011) OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol 104:423\u2013438. \nhttps:\/\/doi.org\/10.1007\/s11060-010-0509-x","journal-title":"J Neurooncol"},{"key":"2002_CR76","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41379-018-0103-x","volume":"31","author":"DN Palsgrove","year":"2018","unstructured":"Palsgrove DN, Brosnan-Cashman JA, Giannini C, Raghunathan A, Jentoft M, Bettegowda C et al (2018) Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Mod Pathol 31:1787\u20131800. \nhttps:\/\/doi.org\/10.1038\/s41379-018-0103-x","journal-title":"Mod Pathol"},{"key":"2002_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yebeh.2017.05.011","volume":"73","author":"A Pecoraro","year":"2017","unstructured":"Pecoraro A, Arehart E, Gallentine W, Radtke R, Smith E, Pizoli C, Kansagra S et al (2017) Epilepsy in neurofibromatosis type 1. Epilepsy Behav 73:137\u2013141. \nhttps:\/\/doi.org\/10.1016\/j.yebeh.2017.05.011","journal-title":"Epilepsy Behav"},{"key":"2002_CR78","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1038\/onc.2016.464","volume":"36","author":"A Pemov","year":"2017","unstructured":"Pemov A, Li H, Patidar R, Hansen NF, Sindiri S, Hartley SW et al (2017) The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. Oncogene 36:3168. \nhttps:\/\/doi.org\/10.1038\/onc.2016.464","journal-title":"Oncogene"},{"key":"2002_CR79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","volume":"9","author":"HS Phillips","year":"2006","unstructured":"Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157\u2013173. \nhttps:\/\/doi.org\/10.1016\/j.ccr.2006.02.019","journal-title":"Cancer Cell"},{"key":"2002_CR80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","volume":"11","author":"C Philpott","year":"2017","unstructured":"Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M (2017) The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics 11:13\u201313. \nhttps:\/\/doi.org\/10.1186\/s40246-017-0109-3","journal-title":"Hum Genomics"},{"key":"2002_CR81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.23813","volume":"73","author":"WW Pong","year":"2013","unstructured":"Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH (2013) Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 73:303\u2013308. \nhttps:\/\/doi.org\/10.1002\/ana.23813","journal-title":"Ann Neurol"},{"key":"2002_CR82","doi-asserted-by":"publisher","first-page":"e021800","DOI":"10.1136\/bmjopen-2018-021800","volume":"8","author":"NA Pride","year":"2018","unstructured":"Pride NA, Barton B, Hutchins P, Coghill DR, Korgaonkar MS, Hearps SJC et al (2018) Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. BMJ Open 8:e021800. \nhttps:\/\/doi.org\/10.1136\/bmjopen-2018-021800","journal-title":"BMJ Open"},{"key":"2002_CR83","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","volume":"136","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE et al (2018) Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol 136:273\u2013291. \nhttps:\/\/doi.org\/10.1007\/s00401-018-1837-8","journal-title":"Acta Neuropathol"},{"key":"2002_CR84","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/modpathol.2013.79","volume":"26","author":"GF Reis","year":"2013","unstructured":"Reis GF, Bloomer MM, Perry A, Phillips JJ, Grenert JP, Karnezis AN et al (2013) Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system. Mod Pathol 26:1279. \nhttps:\/\/doi.org\/10.1038\/modpathol.2013.79","journal-title":"Mod Pathol"},{"key":"2002_CR85","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00401-010-0784-9","volume":"121","author":"EF Rodriguez","year":"2011","unstructured":"Rodriguez EF, Scheithauer BW, Giannini C, Rynearson A, Cen L, Hoesley B et al (2011) PI3\u00a0K\/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol 121:407\u2013420. \nhttps:\/\/doi.org\/10.1007\/s00401-010-0784-9","journal-title":"Acta Neuropathol"},{"key":"2002_CR86","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bpa.12646","volume":"21","author":"FJ Rodriguez","year":"2019","unstructured":"Rodriguez FJ, Brosnan-Cashman JA, Allen SJ, Vizcaino MA, Giannini C, Camelo-Piragua S et al (2019) Alternative lengthening of telomeres, ATRX loss and H3-K27\u00a0M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathol 21:126\u2013140. \nhttps:\/\/doi.org\/10.1111\/bpa.12646","journal-title":"Brain Pathol"},{"key":"2002_CR87","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/NEN.0b013e3182656ef8","volume":"71","author":"FJ Rodriguez","year":"2012","unstructured":"Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, Rushing EJ, Ligon KL, Vena N et al (2012) BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol 71:789\u2013794. \nhttps:\/\/doi.org\/10.1097\/NEN.0b013e3182656ef8","journal-title":"J Neuropathol Exp Neurol"},{"key":"2002_CR88","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/NEN.0b013e318165eb75","volume":"67","author":"FJ Rodriguez","year":"2008","unstructured":"Rodriguez FJ, Perry A, Gutmann DH, O\u2019Neill BP, Leonard J, Bryant S et al (2008) Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 67:240\u2013249. \nhttps:\/\/doi.org\/10.1097\/NEN.0b013e318165eb75","journal-title":"J Neuropathol Exp Neurol"},{"key":"2002_CR89","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00401-016-1619-0","volume":"132","author":"FJ Rodriguez","year":"2016","unstructured":"Rodriguez FJ, Vizcaino MA, Blakeley J, Heaphy CM (2016) Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas. Acta Neuropathol 132:761\u2013763. \nhttps:\/\/doi.org\/10.1007\/s00401-016-1619-0","journal-title":"Acta Neuropathol"},{"key":"2002_CR90","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1212\/01.WNL.0000150544.00016.69","volume":"64","author":"TL Rosser","year":"2005","unstructured":"Rosser TL, Vezina G, Packer RJ (2005) Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 64:553. \nhttps:\/\/doi.org\/10.1212\/01.WNL.0000150544.00016.69","journal-title":"Neurology"},{"key":"2002_CR91","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00381-015-2887-z","volume":"31","author":"HH Ryu","year":"2015","unstructured":"Ryu HH, Jung TY, Lee GJ, Lee KH, Jung SH, Jung S et al (2015) Differences in the clinical courses of pediatric and adult pilocytic astrocytomas with progression: a single-institution study. Childs Nerv Syst 31:2063\u20132069. \nhttps:\/\/doi.org\/10.1007\/s00381-015-2887-z","journal-title":"Childs Nerv Syst"},{"key":"2002_CR92","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/humu.22392","volume":"34","author":"A Sabbagh","year":"2013","unstructured":"Sabbagh A, Pasmant E, Imbard A, Luscan A, Soares M, Blanch\u00e9 H et al (2013) NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French Experience. Hum Mutat 34:1510\u20131518. \nhttps:\/\/doi.org\/10.1002\/humu.22392","journal-title":"Hum Mutat"},{"key":"2002_CR93","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/000331977402500803","volume":"25","author":"WR Salyer","year":"1974","unstructured":"Salyer WR, Salyer DC (1974) The vascular lesions of neurofibromatosis. Angiology 25:510\u2013519. \nhttps:\/\/doi.org\/10.1177\/000331977402500803","journal-title":"Angiology"},{"key":"2002_CR94","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-12-0334","volume":"72","author":"WL See","year":"2012","unstructured":"See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO (2012) Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res 72:3350\u20133359. \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0334","journal-title":"Cancer Res"},{"key":"2002_CR95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10014-017-0302-z","volume":"35","author":"I Shibahara","year":"2018","unstructured":"Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R et al (2018) Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol 35:10\u201318. \nhttps:\/\/doi.org\/10.1007\/s10014-017-0302-z","journal-title":"Brain Tumor Pathol"},{"key":"2002_CR96","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.1004829107","volume":"107","author":"C Shilyansky","year":"2010","unstructured":"Shilyansky C, Karlsgodt KH, Cummings DM, Sidiropoulou K, Hardt M, James AS et al (2010) Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci USA 107:13141\u201313146. \nhttps:\/\/doi.org\/10.1073\/pnas.1004829107","journal-title":"Proc Natl Acad Sci USA"},{"key":"2002_CR97","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1242\/dmm.009779","volume":"5","author":"J Shin","year":"2012","unstructured":"Shin J, Padmanabhan A, de Groh ED, Lee J-S, Haidar S, Dahlberg S et al (2012) Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech 5:881\u2013894. \nhttps:\/\/doi.org\/10.1242\/dmm.009779","journal-title":"Dis Model Mech"},{"key":"2002_CR98","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.7759\/cureus.857","volume":"8","author":"EP Sieg","year":"2016","unstructured":"Sieg EP, Payne R, Langan S, Specht CS (2016) Case report: a rosette-forming glioneuronal tumor in the tectal plate in a patient with neurofibromatosis type I. Cureus 8:e857. \nhttps:\/\/doi.org\/10.7759\/cureus.857","journal-title":"Cureus"},{"key":"2002_CR99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/NEN.0b013e3182032d37","volume":"70","author":"GW Simmons","year":"2011","unstructured":"Simmons GW, Pong WW, Emnett RJ, White CR, Gianino SM, Rodriguez FJ et al (2011) Neurofibromatosis-1 heterozygosity increases microglia in a spatially- and temporally-restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 70:51\u201362. \nhttps:\/\/doi.org\/10.1097\/NEN.0b013e3182032d37","journal-title":"J Neuropathol Exp Neurol"},{"key":"2002_CR100","doi-asserted-by":"publisher","first-page":"47206","DOI":"10.18632\/oncotarget.17589","volume":"8","author":"AC Solga","year":"2017","unstructured":"Solga AC, Toonen JA, Pan Y, Cimino PJ, Ma Y, Castillon GA et al (2017) The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Oncotarget 8:47206\u201347215. \nhttps:\/\/doi.org\/10.18632\/oncotarget.17589","journal-title":"Oncotarget"},{"key":"2002_CR101","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fneur.2017.00087","volume":"8","author":"CE Stafstrom","year":"2017","unstructured":"Stafstrom CE, Staedtke V, Comi AM (2017) Epilepsy mechanisms in neurocutaneous disorders: tuberous sclerosis complex, neurofibromatosis type 1, and Sturge-Weber syndrome. Front Neurol 8:87. \nhttps:\/\/doi.org\/10.3389\/fneur.2017.00087","journal-title":"Front Neurol"},{"key":"2002_CR102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ajpath.2013.09.022","volume":"184","author":"BK Stansfield","year":"2014","unstructured":"Stansfield BK, Bessler WK, Mali R, Mund JA, Downing BD, Kapur R et al (2014) Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Am J Pathol 184:79\u201385. \nhttps:\/\/doi.org\/10.1016\/j.ajpath.2013.09.022","journal-title":"Am J Pathol"},{"key":"2002_CR103","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ajpath.2013.09.022","volume":"184","author":"BK Stansfield","year":"2014","unstructured":"Stansfield BK, Bessler WK, Mali R, Mund JA, Downing BD, Kapur R et al (2014) Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Am J Pathol 184:79\u201385. \nhttps:\/\/doi.org\/10.1016\/j.ajpath.2013.09.022","journal-title":"Am J Pathol"},{"key":"2002_CR104","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/ajmg.a.37622","volume":"170","author":"RE Strowd 3rd","year":"2016","unstructured":"Strowd RE 3rd, Rodriguez FJ, McLendon RE, Vredenburgh JJ, Chance AB, Jallo G et al (2016) Histologically benign, clinically aggressive: progressive non-optic pathway pilocytic astrocytomas in adults with NF1. Am J Med Genet A 170:1455\u20131461. \nhttps:\/\/doi.org\/10.1002\/ajmg.a.37622","journal-title":"Am J Med Genet A"},{"key":"2002_CR105","first-page":"7570","volume":"8","author":"H Takei","year":"2015","unstructured":"Takei H, Rouah E, Bhattacharjee MB (2015) Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review. Int J Clin Exp Pathol 8:7570\u20137574","journal-title":"Int J Clin Exp Pathol"},{"key":"2002_CR106","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.22005","volume":"67","author":"LS Talman","year":"2010","unstructured":"Talman LS, Bisker ER, Sackel DJ, Long DA Jr, Galetta KM, Ratchford JN et al (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 67:749\u2013760. \nhttps:\/\/doi.org\/10.1002\/ana.22005","journal-title":"Ann Neurol"},{"key":"2002_CR107","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1161\/STROKEAHA.115.011406","volume":"47","author":"R Terry Anna","year":"2016","unstructured":"Terry Anna R, Jordan Justin T, Schwamm L, Plotkin Scott R (2016) Increased risk of cerebrovascular disease among patients with neurofibromatosis type 1. Stroke 47:60\u201365. \nhttps:\/\/doi.org\/10.1161\/STROKEAHA.115.011406","journal-title":"Stroke"},{"key":"2002_CR108","doi-asserted-by":"publisher","first-page":"ED23","DOI":"10.7860\/jcdr\/2017\/26685.9713","volume":"11","author":"K Thara","year":"2017","unstructured":"Thara K, Sharma R, Thiagarajan G, Ramdas A, Varghese RG (2017) Anaplastic pleomorphic xanthoastrocytoma in a case of neurofibromatosis type 1: a case report. J Clin Diagn Res JCDR 11:ED23\u2013ED24. \nhttps:\/\/doi.org\/10.7860\/jcdr\/2017\/26685.9713","journal-title":"J Clin Diagn Res JCDR"},{"key":"2002_CR109","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12311-015-0658-8","volume":"14","author":"SP Toelle","year":"2015","unstructured":"Toelle SP, Poretti A, Weber P, Seute T, Bromberg JE, Scheer I et al (2015) Cerebellar hypoplasia and dysmorphia in neurofibromatosis type 1. Cerebellum 14:642\u2013649. \nhttps:\/\/doi.org\/10.1007\/s12311-015-0658-8","journal-title":"Cerebellum"},{"key":"2002_CR110","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/01.rct.0000162406.71300.b7","volume":"29","author":"G Tognini","year":"2005","unstructured":"Tognini G, Ferrozzi F, Garlaschi G, Piazza P, Patti A, Virdis R et al (2005) Brain apparent diffusion coefficient evaluation in pediatric patients with neurofibromatosis type 1. J Comput Assist Tomogr 29:298\u2013304","journal-title":"J Comput Assist Tomogr"},{"key":"2002_CR111","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1093\/hmg\/ddw039","volume":"25","author":"JA Toonen","year":"2016","unstructured":"Toonen JA, Anastasaki C, Smithson LJ, Gianino SM, Li K, Kesterson RA et al (2016) NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. Hum Mol Genet 25:1703\u20131713. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddw039","journal-title":"Hum Mol Genet"},{"key":"2002_CR112","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1084\/jem.20160447","volume":"214","author":"JA Toonen","year":"2017","unstructured":"Toonen JA, Solga AC, Ma Y, Gutmann DH (2017) Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma\u2013induced retinal pathology. J Exp Med 214:17\u201325. \nhttps:\/\/doi.org\/10.1084\/jem.20160447","journal-title":"J Exp Med"},{"key":"2002_CR113","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jns.2018.10.006","volume":"395","author":"M Tsipi","year":"2018","unstructured":"Tsipi M, Poulou M, Fylaktou E, Kosma K, Tsoutsou E, Pons M-R et al (2018) Phenotypic expression of a spectrum of Neurofibromatosis Type 1 (NF1) mutations identified through NGS and MLPA. J Neurol Sci 395:95\u2013105. \nhttps:\/\/doi.org\/10.1016\/j.jns.2018.10.006","journal-title":"J Neurol Sci"},{"key":"2002_CR114","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1212\/01.wnl.0000257095.33125.48","volume":"68","author":"NJ Ullrich","year":"2007","unstructured":"Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD et al (2007) Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 68:932. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000257095.33125.48","journal-title":"Neurology"},{"key":"2002_CR115","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo E, Lepp\u00e4virta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135:904\u2013906. \nhttps:\/\/doi.org\/10.1038\/jid.2014.465","journal-title":"J Invest Dermatol"},{"key":"2002_CR116","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/BF01377205","volume":"26","author":"S Van Es","year":"1996","unstructured":"Van Es S, North KN, McHugh K, De Silva M (1996) MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol 26:478\u2013487","journal-title":"Pediatr Radiol"},{"key":"2002_CR117","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17:98. \nhttps:\/\/doi.org\/10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"key":"2002_CR118","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2011.07.046","volume":"119","author":"F Viola","year":"2012","unstructured":"Viola F, Villani E, Natacci F, Selicorni A, Melloni G, Vezzola D et al (2012) Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. Ophthalmology 119:369\u2013375. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2011.07.046","journal-title":"Ophthalmology"},{"key":"2002_CR119","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.humpath.2015.05.014","volume":"46","author":"MA Vizca\u00edno","year":"2015","unstructured":"Vizca\u00edno MA, Shah S, Eberhart CG, Rodriguez FJ (2015) Clinicopathologic implications of NF1 gene alterations in diffuse gliomas(). Hum Pathol 46:1323\u20131330. \nhttps:\/\/doi.org\/10.1016\/j.humpath.2015.05.014","journal-title":"Hum Pathol"},{"key":"2002_CR120","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1212\/WNL.0000000000002928","volume":"87","author":"KS Walsh","year":"2016","unstructured":"Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA et al (2016) Neurocognitive outcomes in neurofibromatosis clinical trials: recommendations for the domain of attention. Neurology 87:S21\u2013S30. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000002928","journal-title":"Neurology"},{"key":"2002_CR121","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/dmcn.12038","volume":"55","author":"KS Walsh","year":"2013","unstructured":"Walsh KS, Velez JI, Kardel PG, Imas DM, Muenke M, Packer RJ et al (2013) Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 55:131\u2013138. \nhttps:\/\/doi.org\/10.1111\/dmcn.12038","journal-title":"Dev Med Child Neurol"},{"key":"2002_CR122","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1158\/0008-5472.CAN-09-3769","volume":"70","author":"NM Warrington","year":"2010","unstructured":"Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnica-Worms D et al (2010) Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res 70:5717","journal-title":"Cancer Res"},{"key":"2002_CR123","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/jnr.20485","volume":"81","author":"JJ Watters","year":"2005","unstructured":"Watters JJ, Schartner JM, Badie B (2005) Microglia function in brain tumors. J Neurosci Res 81:447\u2013455. \nhttps:\/\/doi.org\/10.1002\/jnr.20485","journal-title":"J Neurosci Res"},{"key":"2002_CR124","doi-asserted-by":"publisher","first-page":"e120402","DOI":"10.1172\/jci.insight.120402","volume":"3","author":"KA White","year":"2018","unstructured":"White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR et al (2018) A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight 3:e120402. \nhttps:\/\/doi.org\/10.1172\/jci.insight.120402","journal-title":"JCI Insight"},{"key":"2002_CR125","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cge.12904","volume":"91","author":"K Wimmer","year":"2016","unstructured":"Wimmer K, Rosenbaum T, Messiaen L (2016) Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91:507\u2013519. \nhttps:\/\/doi.org\/10.1111\/cge.12904","journal-title":"Clin Genet"},{"key":"2002_CR126","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.celrep.2014.07.054","volume":"8","author":"MA Wolman","year":"2014","unstructured":"Wolman MA, de Groh ED, McBride SM, Jongens TA, Granato M, Epstein JA (2014) Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1. Cell reports 8:1265\u20131270. \nhttps:\/\/doi.org\/10.1016\/j.celrep.2014.07.054","journal-title":"Cell reports"},{"key":"2002_CR127","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1038\/s41598-018-24046-2","volume":"8","author":"MD Wood","year":"2018","unstructured":"Wood MD, Mukherjee J, Pieper RO (2018) Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro. Sci Rep 8:5805. \nhttps:\/\/doi.org\/10.1038\/s41598-018-24046-2","journal-title":"Sci Rep"},{"key":"2002_CR128","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2005.07.004","volume":"8","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP et al (2005) Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119\u2013130. \nhttps:\/\/doi.org\/10.1016\/j.ccr.2005.07.004","journal-title":"Cancer Cell"},{"key":"2002_CR129","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1242\/dev.02162","volume":"132","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C et al (2005) Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 132:5577","journal-title":"Development"},{"key":"2002_CR130","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1101\/gad.862101","volume":"15","author":"Y Zhu","year":"2001","unstructured":"Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ et al (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15:859\u2013876. \nhttps:\/\/doi.org\/10.1101\/gad.862101","journal-title":"Genes Dev"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-019-02002-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-019-02002-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-019-02002-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T09:03:11Z","timestamp":1589619791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-019-02002-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2002"],"URL":"https:\/\/doi.org\/10.1007\/s00401-019-02002-2","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"6 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}